Barricade-delay study
Recruiting until: 31-Dec-2027
A Phase 3, Double-Blind, Randomized, Placebo-Controlled study of Baricitinib to delay Stage 3 Type 1 Diabetes in at-risk participants aged ≥1 to <36 years.
Recruiting sites:
- The Royal London Children’s Hospital
- Southampton General Hospital
- Noah’s Ark Children’s Hospital, Cardiff
- Addenbrooke’s Hospital, Cambridge
Summary
Trial of a new medication in people with at-risk (Stage 1b & Stage 2) type 1 diabetes aged 1-36 years.
Aim
Delay the onset of Stage 3 Type 1 Diabetes
Eligibility to take part
- Age 1-36 years
- History of at least one documented occasion of at least two diabetes-related autoantibodies
If you are interested in taking part, please click the “Get Involved” button below:
What will I be asked to do?
You will be required to visit the research or your doctor’s office at fixed interval, where study-specific tasks will be performed like physical examination, check on medication, Continuous Glucose Monitoring assessment etc. The study could continue for up to 5 years, which includes, screening period, treatment period, follow-up period and continued access period.
Who is running this study?
This study is sponsored by Eli Lilly and Company. The purpose of this research study is to learn more about baricitinib, a medicine that may be able to delay the start of Stage 3 type 1 diabetes (which is when T1D is typically diagnosed, i.e, when symptoms appear and clinical diagnosis is made) in people who are in the early stages of the disease (Stage 1b or Stage 2).
